This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cortez-Retamozo, V. Articles by Revets, H. Search for Related Content PubMed PubMed Citation Articles by Cortez-Retamozo, V. Articles by Revets, H.

Efficient Cancer Therapy with a Nanobody-Based Conjugate

¹ Department of Molecular and Cellular Interactions, Flanders Interuniversity Institute for Biotechnology, Vrije Universiteit Brussel, Brussels, Belgium; ² Seattle Genetics, Bothell, Washington; and ³ Central Veterinary Research Laboratories, Dubai, United Arab Emirates

Nanobodies are the smallest fragments of naturally occurring single-domain antibodies that have evolved to be fully functional in the absence of a light chain. Nanobodies are strictly monomeric, very stable, and highly soluble entities. We identified a nanobody with subnanomolar affinity for the human tumor-associated carcinoembryonic antigen. This nanobody was conjugated to Enterobacter cloacae ß-lactamase, and its site-selective anticancer prodrug activation capacity was evaluated. The conjugate was readily purified in high yields without aggregation or loss of functionality of the constituents. In vitro experiments showed that the nanobody–enzyme conjugate effectively activated the release of phenylenediamine mustard from the cephalosporin nitrogen mustard prodrug 7-(4-carboxybutanamido) cephalosporin mustard at the surface of carcinoembryonic antigen-expressing LS174T cancer cells. In vivo studies demonstrated that the conjugate had an excellent biodistribution profile and induced regressions and cures of established tumor xenografts. The easy generation and manufacturing yield of nanobody-based conjugates together with their potent antitumor activity make nanobodies promising vehicles for new generation cancer therapeutics.

This article has been cited by other articles:

				C. Vincke, R. Loris, D. Saerens, S. Martinez-Rodriguez, S. Muyldermans, and K. Conrath General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold J. Biol. Chem., January 30, 2009; 284(5): 3273 - 3284. [Abstract] [Full Text] [PDF]

				A. Forsman, E. Beirnaert, M. M. I. Aasa-Chapman, B. Hoorelbeke, K. Hijazi, W. Koh, V. Tack, A. Szynol, C. Kelly, A. McKnight, et al. Llama Antibody Fragments with Cross-Subtype Human Immunodeficiency Virus Type 1 (HIV-1)-Neutralizing Properties and High Affinity for HIV-1 gp120 J. Virol., December 15, 2008; 82(24): 12069 - 12081. [Abstract] [Full Text] [PDF]

				F. Koch-Nolte, J. Reyelt, B. Schossow, N. Schwarz, F. Scheuplein, S. Rothenburg, F. Haag, V. Alzogaray, A. Cauerhff, and F. A. Goldbaum Single domain antibodies from llama effectively and specifically block T cell ecto-ADP-ribosyltransferase ART2.2 in vivo FASEB J, November 1, 2007; 21(13): 3490 - 3498. [Abstract] [Full Text] [PDF]

				R. M. Sharkey, H. Karacay, W. J. McBride, E. A. Rossi, C.-H. Chang, and D. M. Goldenberg Bispecific Antibody Pretargeting of Radionuclides for Immuno Single-Photon Emission Computed Tomography and Immuno Positron Emission Tomography Molecular Imaging: An Update Clin. Cancer Res., September 15, 2007; 13(18): 5577s - 5585s. [Abstract] [Full Text] [PDF]

				A. Rothe, R. J. Hosse, and B. E. Power In vitro display technologies reveal novel biopharmaceutics FASEB J, August 1, 2006; 20(10): 1599 - 1610. [Abstract] [Full Text] [PDF]

				R. M. Sharkey and D. M. Goldenberg Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates CA Cancer J Clin, July 1, 2006; 56(4): 226 - 243. [Abstract] [Full Text] [PDF]

				F. A. Harding, A. D. Liu, M. Stickler, O. J. Razo, R. Chin, N. Faravashi, W. Viola, T. Graycar, V. P. Yeung, W. Aehle, et al. A {beta}-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy Mol. Cancer Ther., November 1, 2005; 4(11): 1791 - 1800. [Abstract] [Full Text] [PDF]

				D. Saerens, J. Kinne, E. Bosmans, U. Wernery, S. Muyldermans, and K. Conrath Single Domain Antibodies Derived from Dromedary Lymph Node and Peripheral Blood Lymphocytes Sensing Conformational Variants of Prostate-specific Antigen J. Biol. Chem., December 10, 2004; 279(50): 51965 - 51972. [Abstract] [Full Text] [PDF]